Impel Pharmaceuticals develops and commercializes therapies for patients with central nervous system disease in the United States. Their lead product candidate, Trudhesa, is a nasal formulation of dihydroergotamine used in treating migraines. Impel Pharmaceuticals is currently developing two other nasal formulations for the treatment of aggression in autism spectrum disorder and Parkinson's disease.